Bio-Path Holdings Files 8-K Report

TL;DR

BPTH filed an 8-K. Check for updates on financials/events.

AI Summary

On March 27, 2024, Bio-Path Holdings, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and business operations. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Bio-Path Holdings, Inc. is providing updated information to the SEC, which could include material business developments or financial disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events or financial distress.

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant
• 0001558370-24-004012 (filing_id) — Accession Number
• March 27, 2024 (date) — Report Date
• Delaware (jurisdiction) — State of Incorporation
• 77401 (zip_code) — Business Address Zip
• 832-742-1357 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
• $3.99 — "Common Stock"), at a purchase price of $3.99 per share (the "Registered Direct Offer
• $3.865 — ect Offering, with an exercise price of $3.865 per share. A copy of the legal opinio

Filing Documents

• bpth-20240327x8k.htm (8-K) — 42KB
• bpth-20240327xex5d1.htm (EX-5.1) — 17KB
• bpth-20240327xex5d1001.jpg (GRAPHIC) — 4KB
• bpth-20240327xex5d1002.jpg (GRAPHIC) — 1KB
• 0001558370-24-004012.txt ( ) — 189KB
• bpth-20240327.xsd (EX-101.SCH) — 3KB
• bpth-20240327_lab.xml (EX-101.LAB) — 16KB
• bpth-20240327_pre.xml (EX-101.PRE) — 10KB
• bpth-20240327x8k_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. As previously disclosed in the Current Report on Form 8-K of Bio-Path Holdings, Inc. (the "Company") filed on March 25, 2024, the Company entered into a securities purchase agreement (the "Purchase Agreement") on March 25, 2024 with a certain institutional and accredited investor for the sale by the Company of 75,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $3.99 per share (the "Registered Direct Offering"). In a concurrent private placement, the Company also agreed pursuant to the Purchase Agreement to issue to the investor in the Registered Direct Offering warrants to purchase up to 75,000 shares of Common Stock, which represent 100% of the number of shares of Common Stock purchased in the Registered Direct Offering, with an exercise price of $3.865 per share. A copy of the legal opinion of Winstead PC relating to the legality of the issuance and sale of the shares of Common Stock in the Registered Direct Offering is filed herewith as Exhibit 5.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 5.1* Opinion of Winstead PC 23.1* Consent of Winstead PC (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: March 27, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR